Aktis Oncology (NASDAQ:AKTS) Hits New 12-Month Low – What’s Next?

Shares of Aktis Oncology (NASDAQ:AKTS) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $19.02 and last traded at $20.50, with a volume of 323657 shares. The stock had previously closed at $21.35.

Aktis Oncology Stock Down 3.1%

The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.28 and a current ratio of 0.32. The firm has a market cap of $3.20 billion, a price-to-earnings ratio of -55.89 and a beta of 1.91.

Insiders Place Their Bets

In other Aktis Oncology news, Director Ecor1 Capital, Llc bought 2,222,222 shares of the business’s stock in a transaction on Monday, January 12th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $39,999,996.00. Following the transaction, the director owned 4,348,658 shares in the company, valued at approximately $78,275,844. This trade represents a 104.50% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Helen Susan Kim bought 835,000 shares of the stock in a transaction on Monday, January 12th. The shares were acquired at an average cost of $18.00 per share, with a total value of $15,030,000.00. Following the acquisition, the director directly owned 5,671,825 shares in the company, valued at approximately $102,092,850. This trade represents a 17.26% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders bought 3,892,222 shares of company stock valued at $70,059,996. 3.30% of the stock is currently owned by insiders.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.